Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Qiagen N.V. (QGEN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 6,613,767
  • Shares Outstanding, K 225,880
  • Annual Sales, $ 1,338 M
  • Annual Income, $ 80,400 K
  • 36-Month Beta 1.08
  • Price/Sales 4.84
  • Price/Cash Flow 13.28
  • Price/Book 2.54

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.74 +5.55%
on 04/11/17
29.66 -1.28%
on 04/24/17
+0.35 (+1.21%)
since 03/24/17
3-Month
27.51 +6.43%
on 01/25/17
30.25 -3.21%
on 03/15/17
+0.80 (+2.79%)
since 01/24/17
52-Week
20.71 +41.40%
on 06/27/16
30.25 -3.21%
on 03/15/17
+4.50 (+18.17%)
since 04/22/16

Most Recent Stories

More News
Separation Systems for Commercial Biotechnology Market 2017: Key Players are Thermo Fisher Scientific, Agilent Technologies, Bio-Rad Laboratories, Danaher, Qiagen N.V., Merck and Waters - Research and Markets

Research and Markets has announced the addition of the "Separation Systems for Commercial Biotechnology" report to their offering.

MRK : 62.14 (+0.40%)
QGEN : 29.28 (+2.06%)
Qiagen (QGEN) Down 2.6% Since Earnings Report: Can It Rebound?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QGEN : 29.28 (+2.06%)
QIAGEN Posts 2016 Annual Report on its Website

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) has posted its 2016 Annual Report on its website at http://www.qiagen.com/About-Us/Investors/Financial-Information/Financial-Reports. QIAGEN's Annual Report...

QGEN : 29.28 (+2.06%)
QIAGEN N.V. to Report First Quarter 2017 Results

QIAGEN N.V. (Nasdaq: QGEN) (Frankfurt: QIA) plans to release its report on results for the first quarter of 2017 on Tuesday, May 2, at approximately 22:00 Central European Time (CET) / 16:00 Eastern Standard...

QGEN : 29.28 (+2.06%)
QIAGEN Releases Favorable GeneReader Results, Expands in NGS

QIAGEN N.V. (QGEN) recently has validated its GeneReader NGS System and published five new independent studies.

ENZ : 8.80 (+0.23%)
HSKA : 107.40 (+2.12%)
QGEN : 29.28 (+2.06%)
GLPG : 85.17 (-0.78%)
QIAGEN Expands Liquid Biopsy Pipeline with AR-V7 Test in Prostate Cancer

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it is commercializing the Research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant...

QGEN : 29.28 (+2.06%)
QIAGEN Joins CANCER-ID Consortium for Liquid Biopsy Workflows

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced it has joined CANCER-ID, a public-private consortium aiming to establish standard protocols and clinical validation for blood-based...

QGEN : 29.28 (+2.06%)
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics

QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.

OSUR : 12.69 (+0.16%)
ZLTQ : 56.49 (-0.02%)
QGEN : 29.28 (+2.06%)
INGN : 80.92 (+2.20%)
QIAGEN Launches First FDA-cleared JAK2 Test for Certain Type of Leukemia

QIAGEN N.V. (NASDAQ: QGEN; FRANKFURT PRIME STANDARD: QIA) today announced the U.S. launch of its ipsogen® JAK2 RGQ PCR Kit (ipsogen JAK2 assay), which was cleared by the U.S. Food and Drug Administration...

QGEN : 29.28 (+2.06%)
Look for Shares of QIAGEN to Potentially Pullback after Yesterday's 1.61% Rise

QIAGEN (NASDAQ:QGEN) traded in a range yesterday that spanned from a low of $29.29 to a high of $29.91. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $29.70...

QGEN : 29.28 (+2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More

Business Summary

Qiagen NV produces biomedical and genetic products, products for separating and purifying nucleic acids for gene-based drug screening, nucleic acid-based clinical diagnostics, genetic vaccination and gene therapy.

See More

Support & Resistance

2nd Resistance Point 29.81
1st Resistance Point 29.54
Last Price 29.28
1st Support Level 29.13
2nd Support Level 28.99

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.